Navigation Links
Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms
Date:7/28/2011

p>Second quarter net sales of Sanofi were euro 8,349 million, up 0.5% on a reported basis. At constant exchange rates, sales were up 6.9%, reflecting the acquisition of Genzyme (euro 796 million) and the impact from U.S. health- care reform, EU austerity measures, and the loss of euro 778 million of sales due to generic competition. "Other revenues" were euro 422 million, an increase of 2.4%, reflecting growth of Plavix® in the U.S. partially offset by an unfavorable dollar effect.

Gross profit reached euro 6,183 million, up 1.8% at constant exchange rates or down 5.0% on a reported basis. The ratio of cost of sales to net sales was 31.0%, 4.4 percentage points higher than in Q2 2010, but close to Q1 2011 level (30.4%), mainly due to the impact of generic competition (accounted for 2.5 percentage points) as well as exchange rate impact.

Research and development expenses were euro 1,197 million, an increase of 7.0% (or 12.6% at constant exchange rates). Excluding Genzyme, R&D expenses decreased 1.0% at constant exchange rates. The ratio of R&D expenses to net sales was 14.3%, up 0.8 percentage point versus the second quarter of 2010.

Selling and general expenses reached euro 2,268 million, an increase of 6.7% (or 13.3% at constant exchange rates). Excluding Genzyme, SG&A expenses were stable (+0.1%) at constant exchange rates and included the global roll-out costs of Jevtana® in EU, investment in Allegra® OTC in the U.S. and increased promotional effort on Lantus® in the U.S. The ratio of selling and general expenses to net sales was 27.2%, 1.6 percentage points higher than Q2 2010.

Other current operating income net of expenses showed a net income of euro 7 million versus net income of euro 27 million in the second quarter of 2010 and included euro 23 million of fees related to the acquisition of Genzyme. This line also includes a slight forei
'/>"/>

SOURCE Sanofi
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. New Senior Executives Appointed at Sanofi:
2. VR Business Sales, Mergers & Acquisitions Charlotte Completes Sale of Penrod Medical Equipment
3. Global Medical Devices Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Marketing Spend and Sales Strategies
4. TPI Ships Macrolide API Samples for International Sales Standard Testing
5. Unilife Starts Unifill Syringe Sales to Another Pharmaceutical Customer
6. Burlington Medical Supplies Reorganizes Sales and Marketing Operations
7. HASCO Medical Inc. Names Mike Dumais the Vice President of Sales for Southern Medical and Mobility
8. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
9. With Launch of New ActiveHome Monitoring System, ActiveCare Announces New Head of Sales and Marketing
10. TPI Signs Macrolide API International Sales and Marketing Agreement
11. CellerateRX TV Commercials Begin Airing on Fox News Network via Geraldo at Large and Fox News Sunday Programs, Expanding the Direct-To-Consumer Sales Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 After 6 months of careful ... here - the new programme for the next Cool Chain ... our global Cool Chain series, has just been released! ... As the lines between supply chain, logistics, QA and ... that is broad and yet specific, focused and yet accessible, ...
(Date:9/18/2014)... Calif. , Sept. 18, 2014   ... ), a biopharmaceutical company leading the discovery and ... it has initiated its ATHENA natural history of ... life-threatening genetic kidney disease with no approved therapy. ... natural decline of renal function markers such as ...
(Date:9/18/2014)... , Sept. 18, 2014  RXi Pharmaceuticals ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that the ... Geert Cauwenbergh , will present at ... Conference on Wednesday, September 24, 2014 at ...
Breaking Medicine Technology:Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3
... MADISON, N.J., March 28, 2011 Quest Diagnostics Incorporated ... of diagnostic testing, information and services, announced today it ... subsidiary, Spark Acquisition Corporation, for all of the outstanding ... (Nasdaq: CRA ), one of the world,s ...
... (Nasdaq: VRUS ) today announced that it will ... Study of the Liver (EASL) on Saturday, April 2, 2011 ... Pharmasset,s progress on the programs that are the subject of ... a simultaneous webcast of this event via the internet, log ...
Cached Medicine Technology:Quest Diagnostics Commences Tender Offer for Acquisition of Celera 2Quest Diagnostics Commences Tender Offer for Acquisition of Celera 3Pharmasset to Webcast an Investor Event From the EASL Meeting 2Pharmasset to Webcast an Investor Event From the EASL Meeting 3
(Date:9/18/2014)... September 18, 2014 Relias Learning, the leader ... human services markets, today announced it has been named to ... private companies in America. , In the three-year period from ... up almost 2,000 spots on the Inc. 5000 list to ... , “The industries we serve continue to grow, and ...
(Date:9/18/2014)... PlatinumCode, a leading manufacturer and supplier ... the healthcare industry, announced earlier this month that ... their profits of the sale of eligible pink ... announcement, PlatinumCode has launched various marketing efforts to ... hospital labs with their popular “Pink Packs” of ...
(Date:9/18/2014)... “Awesome” is the way Emily W. describes her ... Internship Program at ARDX ( http://www.ardx.net ). Her ... as “Inspirational” and “Life-changing,” respectively. None of these ... be doing during their summer internship. Stacie was ... mindless tasks,” but, instead she was doing real, meaningful ...
(Date:9/18/2014)... HealthDay Reporter WEDNESDAY, Sept. 17, 2014 (HealthDay ... stress disorder symptoms are almost three times more likely to ... The findings don,t prove a direct link between PTSD ... also possible that certain women are prone to food addiction ... research seems to add to existing evidence connecting PTSD to ...
(Date:9/18/2014)... 18, 2014 Fit Body Boot Camp ... fitness business in the country and its popularity, as both ... to grow enormously in 2014. , The company’s annual ... taking place in Costa Mesa, CA on September 26 and ... conferences yet. Founder Bedros Keuilian, who is also considered the ...
Breaking Medicine News(10 mins):Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:PlatinumCode Commits to Donating Five Percent of Profits from the sale of Pink Products to Support Breast Cancer Awareness 2Health News:ARDX Internship Helps Students to START on the Right Business Path 2Health News:ARDX Internship Helps Students to START on the Right Business Path 3Health News:ARDX Internship Helps Students to START on the Right Business Path 4Health News:PTSD Link to Food Addiction Seen in Report 2Health News:PTSD Link to Food Addiction Seen in Report 3Health News:With Fit Body Boot Camp World Conference Nearing, Founder Explains the Fitness Boot Camp Franchise’s Success 2Health News:With Fit Body Boot Camp World Conference Nearing, Founder Explains the Fitness Boot Camp Franchise’s Success 3
... Sales increase 73% over Third Quarter 2007, EMERYVILLE, ... ) today reported its financial results,for the three and ... of $12.2 million, or $0.21 per diluted share, for ... $0.6 million, or $0.01 per diluted share,in the same ...
... 6 Pharmos Corporation,(Nasdaq: PARS ) today reported results ... a net loss of $2.8 million, or $0.11 per,share, for ... $3.5 million,or $0.14 per share, in the third quarter 2007. ... The decrease in net loss for the third quarter ...
... and service levels were key reasons, says union,president, ... Paul N. Urick, R.Ph., announced today that the ... its Participating Employers Health,and Welfare Fund have agreed ... members pharmacy coverage through FutureScripts. UFCW Local,1776,s new ...
... room doctors, study says , , THURSDAY, Nov. 6 (HealthDay ... at the hands of peers, immediate one-on-one mentoring on ... their risk of becoming victims again, a new study ... for assault injuries -- including gunshot, knife and fist-fight ...
... mostly young children -- infected, bringing total to 79, CDC ... cases of people becoming infected with salmonella traced to dry ... , The outbreak, which started in 2006, marks the first ... source of the bacterial infection in people. , As of ...
... Company Reports Seventeenth Consecutive Quarter Of Growth In ... Inc.,(Nasdaq: GXDX ), a specialized laboratory services ... third quarter of 2008, which includes a,$2.5 million ... prior,periods. This compares to revenues of $16.2 million ...
Cached Medicine News:Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 2Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 3Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 4Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 5Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 6Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 7Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 8Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 9Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 10Health News:Pharmos Corporation Reports 2008 Third Quarter Results 2Health News:Pharmos Corporation Reports 2008 Third Quarter Results 3Health News:Pharmos Corporation Reports 2008 Third Quarter Results 4Health News:Pharmos Corporation Reports 2008 Third Quarter Results 5Health News:FutureScripts(R) Wins Business of UFCW Local 1776 for Pharmacy Benefits 2Health News:FutureScripts(R) Wins Business of UFCW Local 1776 for Pharmacy Benefits 3Health News:FutureScripts(R) Wins Business of UFCW Local 1776 for Pharmacy Benefits 4Health News:Counseling Can Combat Youth Violence 2Health News:Salmonella Outbreak Tied to Dry Dog Food Continues 2Health News:Salmonella Outbreak Tied to Dry Dog Food Continues 3Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 2Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 3Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 4Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 5Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 6Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 7Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 8Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 9Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 10
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
Medicine Products: